Indobufen Noninferior to Aspirin for DAPT After PCI: OPTION

Antiplatelet agent indobufen was noninferior to aspirin in combination with clopidogrel after coronary intervention on both efficacy and safety outcomes, with less mostly minor bleeding.

Related Keywords

Germany , Zhongshan , Anhui , China , Shanghai , United States , Munich , Bayern , California , Irvine , American , Dipti Itchhaporia , Eric Sheila Samson , University Of California , American Heart Association , German Heart Center Munich , Academic Research Consortium , Vascular Institute , American College Of Cardiology , Drug Administration , American Heart Association Scientific Sessions , Hangzhou Zhhongmei Huadong Pharmaceutical Co Ltd , Fudan University , Shanghai Clinical Research Center , National Medical Products Administration , Zhongshan Hospital , Bleeding Academic Research Consortium , Stefanie Sch , Medscape Cardiology , Sheila Samson , Hoag Heart , American College , Interventional Medicine , Clinical Research Special Fund , Zhongshan Hospital Fudan , Heart Association , , Aspirin , Cv , Ardiovascular , Drug Eluting Stent , Atherosclerotic Heart Disease , Therosclerotic Cardiovascular Disease , Oronary Heart Disease , Schemic Heart Disease , Myocardial Infarction , Antiplatelet Agent , Hospitals , Ischemic Stroke , Cox 1 Inhibitor , Yclooxygenase 1 Inhibitor , Percutaneous Coronary Intervention ,